Last updated: May 26, 2026
Umeclidinium Bromide and Vilanterol Trifenatate API Suppliers: Who Makes the Monomers, Salts, and Finished Breo-Compatible Components?
Umeclidinium bromide and vilanterol trifenatate are commercially supplied through a layered vendor structure: (1) API and salt makers, (2) key intermediate suppliers, and (3) inhaler-formulation and device-pack suppliers that support US FDA–scaled development and commercial production. Vendor qualification in this class typically depends on DMF coverage (or letter of access), inhalation-quality particle control, salt/isomer consistency, and inhaler compatibility with device and formulation IP.
The supplier landscape for these two actives is dominated by large, multi-product inhalation and respiratory API players plus specialists that focus on inhaled LOBs and EU/US regulatory supply continuity. The tightest commercial constraint is not synthesis capability alone; it is sustained batch-to-batch impurity control and regulator-ready documentation (DMF, CoA profiles, stability packets, and validation packages).
Which companies supply umeclidinium bromide (API) for inhalation products?
Supplier typologies
- API/salt manufacturers supplying umeclidinium bromide directly to inhalation-formulation sites.
- Intermediate manufacturers producing key umeclidinium-forming blocks (quaternization precursors, salt-forming reagents).
- Contract manufacturing organizations (CMOs) with inhalation focus that handle milling, spray-drying, and DP manufacturing using supplier APIs.
Common qualification gatekeepers for umeclidinium bromide
- DMF/ASMF availability for umeclidinium bromide or umeclidinium (free base) plus salt-manufacturing step.
- Impurity strategy aligned to inhalation thresholds, including nitrosamine risk controls (where applicable).
- Controlled particle size distribution if the supplied API is used directly in inhalation blends (or consistent upstream milling).
Which companies supply vilanterol trifenatate (API) for inhalation products?
Supplier typologies
- API makers supplying vilanterol trifenatate (or vilanterol with defined conversion to the trifenate salt).
- Salt conversion and process specialists that ensure trifenate salt reproducibility across campaigns.
- Inhalation-responsible CMOs that control blending, DP uniformity, and moisture handling.
Key supply requirements for vilanterol trifenatate
- Salt form control for trifenate and consistent counterion stoichiometry.
- Impurity profile consistency and stability at inhaler-ready conditions.
- Packaging compatibility for metered-dose dry powder (DP) supply chains.
How many suppliers exist for umeclidinium bromide and vilanterol trifenatate globally?
A reliable count requires Orange Book and DMF-linked mapping at the product level and vendor disclosures at the CMC level. In practice, the supplier set is smaller than the number of finished product makers because:
- regulatory dossiers concentrate on fewer compliant API sites;
- inhalation-quality control pushes supply toward a limited vendor base;
- campaign economics favor a stable, qualified supply chain over spot sourcing.
Operational reality
- Most brand and authorized generic developers do not dual-source every API step immediately. They often maintain a primary API supplier plus a qualified backup after process development and tech transfer.
Who makes the key intermediates for umeclidinium bromide and vilanterol trifenatate?
Umeclidinium bromide intermediate cluster
- Umeclidinium-forming scaffolds that enable the final salt formation and quaternization steps.
- Salt-forming reagents and controlled counterion handling.
Vilanterol trifenatate intermediate cluster
- Vilanterol-forming intermediates plus trifenate salt formation chemistry.
- Materials controlling stereochemical consistency and salt conversion yield.
Where intermediates typically come from
- intermediate-focused chemical manufacturers supplying building blocks under confidentiality and process-specific acceptance criteria;
- larger API makers that vertically integrate salt formation and final purification.
What inhaler-formulation and device suppliers support umeclidinium/vilanterol combinations?
For commercial dry powder inhaler (DPI) platforms, finished product supply frequently uses:
- DPI formulation CMOs (mixing, milling control, blend uniformity)
- fill-finish and blister/strip packaging lines
- device integration partners that supply inhaler components and assemble at contract sites
In the umeclidinium/vilanterol combination category, the critical operational interface is the match between:
- API particle characteristics (often driven by supplier milling and/or final milling at DP site),
- excipient system and moisture spec,
- device dose delivery performance.
Which suppliers support Breo-compatible umeclidinium/vilanterol CMC packages in the US?
US-ready supply depends on whether a supplier has:
- US DMF coverage that ties to the finished-dose site,
- letter of authorization/access coverage allowing cross-referencing of the API dossier.
Finished-dose manufacturers and authorized generic developers typically route:
- API quality documents via DMF,
- batch release and method validation packages via CMC tech transfer.
What patent and regulatory constraints affect changing suppliers for umeclidinium bromide or vilanterol trifenatate?
Regulatory constraint
- Changing an API supplier can trigger comparability work for impurity profile, particle size, polymorph/salt form, dissolution/dispersion properties, and stability.
Patent/IP constraint
- While upstream API synthesis can be less directly constrained than formulation or device IP, developers still face process claims for specific intermediates, salt formation methods, or purification sequences if they attempt to switch to a non-overlapping route.
How strong is the manufacturing/IP barrier for developing alternative supply of umeclidinium/vilanterol actives?
Barriers are usually driven by:
- control of salt form and impurity profile
- inhalation-specific particle engineering needs
- documented regulatory quality package readiness (DMF or ASMF compliance)
For new entrants attempting API substitution, the hardest part is not “making an API,” it is passing acceptance tests across:
- impurity limits,
- residual solvents,
- polymorph/salt form specs,
- aerosol performance equivalence.
What generic entry risks exist if a new supplier cannot meet umeclidinium/vilanterol specs?
Risks include:
- delayed regulatory approval tied to comparability batches and stability data gaps
- higher rejection rates at CMC review due to impurity and salt form deviations
- inability to support commercial scale economics if the supplier requires extended ramp timelines or different packaging specs
Key Takeaways
- Umeclidinium bromide and vilanterol trifenatate supply is concentrated among qualified API and salt manufacturers with inhalation-grade impurity and salt-form control.
- The effective supplier universe is narrower than the number of finished-dose companies because inhalation CMC readiness and DMF/ASMF coverage constrain vendor switching.
- Supplier changes are CMC-heavy: particle characteristics, impurity profile, and salt conversion reproducibility drive comparability risk.
- Manufacturing and regulatory barriers for alternative sourcing come from documentation readiness (DMF/letters) and inhalation performance equivalence needs, not only synthetic feasibility.
FAQs
-
Can a generic for a umeclidinium/vilanterol DPI switch the API supplier without a new clinical study?
Yes, typically through CMC comparability, but it often requires bridging stability, impurity, and aerosol performance data.
-
Do umeclidinium bromide and vilanterol trifenatate suppliers provide DMF coverage automatically?
Coverage depends on the specific supplier site and whether the dossier is maintained for US use.
-
Is trifenate salt formation a common failure point in supplying vilanterol?
Salt form and counterion stoichiometry consistency are frequent comparability triggers.
-
What matters more for inhalation API: particle size from the supplier or milling at the formulation site?
Both. Supplier particle characteristics set the baseline; formulation-site milling controls final DP performance and uniformity.
-
Do inhaler device partners influence API supplier selection?
Yes. Device dose delivery requirements and moisture/flow specifications can narrow acceptable API and excipient combinations.
References
- (No citable sources were provided in the prompt.)
